Responsibility：
• Develop establish preclinical in vivo models fAlzheimer’s disease (AD),
Parkinson’s disease (PD), stroke, pain-related CNS disorders to evaluate novel
therapeutics.
• Work closely with Medicinal Chemistry, Biologics Discovery, in vitro Pharmacology,
DMPK, Toxicology teams to design execute in vivo pharmacology studies,
supporting target validation, pharmacokinetics (PK), pharmacodynamics (PD).
• Design conduct behavioral, biochemical, molecular assays in rodent
models to assess drug efficacy, mechanism of action (MoA), biomarker
responses.
• Collaborate with cross-functional teams to develop in vivo proof-of-concept (PoC)
studies, ensuring alignment with program milestones.
• Serve as a subject matter expert in CNS disease model development, providing
insights on experimental design, troubleshooting, data interpretation.
• Perform tissue collection biomarker assessments using molecular, histological,
biochemical techniques (IHC, IF, qPCR, ELISA, MSD, Luminex, Western blot).
• Mentmanage juniscientists research associates, providing
scientific/technical guidance, performance feedback, professional development.
• Contribute to the evaluation of new drug targets, MoA studies, proposal第 2 页 共 4 页
preparation fCNS drug discovery programs.
• Support IND-enabling studies participate in regulatory document preparation
fclinical submission.
Qualifications：
• PhD (with at least 3 years of industry experience) in neuroscience,
neuropharmacology, behavioral neuroscience, related fields.
• Hands-on experience in CNS in vivo pharmacology, with proven expertise in AD,
PD, stroke, pain models.
• Proficiency in rodent handling, stereotaxic surgeries, behavioral assays, drug
administration (IV, IP, SC, ICV, IT, PO, etc.).
• Extensive experience in ex vivo neuropharmacology techniques, including flow
cytometry, ELISA, multiplex cytokine analysis, Western blot, transcriptomics
(RNA-seq, proteomics).
• Proven track-record of supporting CNS projects IND submission familiar with
China NMPA/the US FDA IND submission requirements fCNS in vivo
pharmacology.
• Strong ability in literature patent research, analytical thinking, problemsolving.
• Excellent verbal written communication skills in English (CET6/IELTS/TOEFL/GRE
scores preferred).
• Highly collaborative team player with strong interdisciplinary communication
skills.
Key Expertise in Model Establishment Experimental Techniques：第 3 页 共 4 页
Alzheimer’ s Disease (AD) Models
• Transgenic models (e.g., APP/PS1, 5xFAD, Tauopathy models)
• Aβ tau injection models (ICV stereotaxic injection)
• Cognitive behavioral assays (e.g., Morris water maze, novel object recognition, Y-maze,
fear conditioning, radial arm maze)
• Neuroinflammation glial activation assessment
Parkinson’s Disease (PD) Models
• Neurotoxin-based models (e.g., MPTP, 6-OHDA lesion models)
• α-synuclein preformed fibril (PFF) injection models
• Behavioral tests fmotfunction (e.g., rotarod, pole test, open field, gait analysis)
• Dopaminergic neuron degeneration analysis (e.g., TH staining, dopamine
quantification)
Stroke Models
• Middle Cerebral Artery Occlusion (MCAO) model including pMCAO, tMCAO and
eMCAO models
• Photothrombotic ischemia model
• Neurological motfunction assessments (e.g., neurological deficit score, cylinder
test, adhesive removal test)
• Histological molecular assessment of infarct size neuroprotection
Pain-related CNS Disease Models
• Neuropathic pain models (e.g., spinal nerve ligation (SNL), chronic constriction injury
(CCI), chemotherapy-induced neuropathy)
• Inflammatory pain models (e.g., CFA-induced paw inflammation, formalin test)第 4 页 共 4 页
• Pain sensitivity assessments (e.g., von Frey test, hot plate, Hargreaves test, mechanical
allodynia)
More
